| Marwan Abdulaal, MD | |
|
563 Wessel Dr, Fairfield, OH 45014-3668 | |
| (513) 858-6500 | |
| Not Available |
| Full Name | Marwan Abdulaal |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 15 Years |
| Location | 563 Wessel Dr, Fairfield, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912316878 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 35147100 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cei Physicians Psc, Llc | 0749186427 | 145 |
News Archive
ADVENTRX Pharmaceuticals, Inc. announced today that it received a refuse to file letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion). In the letter, the FDA indicated that the data included in the initial submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. FDA identified only the one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX plans to meet with the FDA as soon as possible to discuss its response.
"The number of cases and deaths from breast and cervical cancer is rising in most countries across the world, especially in poorer nations where more women are dying at younger ages, according to a global study of the diseases" by researchers from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, Reuters reports.
Work has officially begun on the construction of a new sanofi pasteur manufacturing facility that will expand the ability of the United States to produce influenza vaccine for both routine influenza immunization and in case of a global influenza pandemic.
A new Phase I study is in the pipeline that would try the effects of low dose radiation therapy for patients with Alzheimer's disease. The researchers from the Beaumont Research Institute in Royal Oak, Michigan are in the process of recruiting patients for their study. The study is titled, "Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's disease".
› Verified 4 days ago
| Entity Name | Cei Physicians Psc, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942296298 PECOS PAC ID: 0749186427 Enrollment ID: O20031211001059 |
News Archive
ADVENTRX Pharmaceuticals, Inc. announced today that it received a refuse to file letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion). In the letter, the FDA indicated that the data included in the initial submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. FDA identified only the one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX plans to meet with the FDA as soon as possible to discuss its response.
"The number of cases and deaths from breast and cervical cancer is rising in most countries across the world, especially in poorer nations where more women are dying at younger ages, according to a global study of the diseases" by researchers from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, Reuters reports.
Work has officially begun on the construction of a new sanofi pasteur manufacturing facility that will expand the ability of the United States to produce influenza vaccine for both routine influenza immunization and in case of a global influenza pandemic.
A new Phase I study is in the pipeline that would try the effects of low dose radiation therapy for patients with Alzheimer's disease. The researchers from the Beaumont Research Institute in Royal Oak, Michigan are in the process of recruiting patients for their study. The study is titled, "Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's disease".
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marwan Abdulaal, MD 563 Wessel Dr, Fairfield, OH 45014-3668 Ph: (513) 858-6500 | Marwan Abdulaal, MD 563 Wessel Dr, Fairfield, OH 45014-3668 Ph: (513) 858-6500 |
News Archive
ADVENTRX Pharmaceuticals, Inc. announced today that it received a refuse to file letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion). In the letter, the FDA indicated that the data included in the initial submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. FDA identified only the one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX plans to meet with the FDA as soon as possible to discuss its response.
"The number of cases and deaths from breast and cervical cancer is rising in most countries across the world, especially in poorer nations where more women are dying at younger ages, according to a global study of the diseases" by researchers from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, Reuters reports.
Work has officially begun on the construction of a new sanofi pasteur manufacturing facility that will expand the ability of the United States to produce influenza vaccine for both routine influenza immunization and in case of a global influenza pandemic.
A new Phase I study is in the pipeline that would try the effects of low dose radiation therapy for patients with Alzheimer's disease. The researchers from the Beaumont Research Institute in Royal Oak, Michigan are in the process of recruiting patients for their study. The study is titled, "Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's disease".
› Verified 4 days ago
John Wathan Gullett Ii, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 563 Wessel Dr, Fairfield, OH 45014 Phone: 513-858-6500 Fax: 513-858-2777 | |
Carol L Anderson, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 5161 Pleasant Ave, Fairfield, OH 45014 Phone: 513-896-1578 Fax: 513-896-1687 | |
Dr. Kelly P O'neill, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 563 Wessel Dr, Fairfield, OH 45014 Phone: 513-858-6500 Fax: 513-858-2777 | |
Dr. Thomas T Macejko, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 563 Wessel Dr, Fairfield, OH 45014 Phone: 513-858-6500 Fax: 513-858-2777 |